<code id='32EBB15254'></code><style id='32EBB15254'></style>
    • <acronym id='32EBB15254'></acronym>
      <center id='32EBB15254'><center id='32EBB15254'><tfoot id='32EBB15254'></tfoot></center><abbr id='32EBB15254'><dir id='32EBB15254'><tfoot id='32EBB15254'></tfoot><noframes id='32EBB15254'>

    • <optgroup id='32EBB15254'><strike id='32EBB15254'><sup id='32EBB15254'></sup></strike><code id='32EBB15254'></code></optgroup>
        1. <b id='32EBB15254'><label id='32EBB15254'><select id='32EBB15254'><dt id='32EBB15254'><span id='32EBB15254'></span></dt></select></label></b><u id='32EBB15254'></u>
          <i id='32EBB15254'><strike id='32EBB15254'><tt id='32EBB15254'><pre id='32EBB15254'></pre></tt></strike></i>

          Home / comprehensive / fashion

          fashion


          fashion

          author:leisure time    Page View:4
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In